EVI1 protein interaction dynamics: Targetable for therapeutic intervention?

DNA-Binding Proteins / metabolism Humans Leukemia, Myeloid, Acute / drug therapy MDS1 and EVI1 Complex Locus Protein / genetics Prognosis Transcription Factors / metabolism

Journal

Experimental hematology
ISSN: 1873-2399
Titre abrégé: Exp Hematol
Pays: Netherlands
ID NLM: 0402313

Informations de publication

Date de publication:
03 2022
Historique:
received: 31 10 2021
revised: 18 12 2021
accepted: 20 12 2021
pubmed: 28 12 2021
medline: 6 5 2022
entrez: 27 12 2021
Statut: ppublish

Résumé

High expression of the transcriptional regulator EVI1 encoded at the MECOM locus at 3q26 is one of the most aggressive oncogenic drivers in acute myeloid leukemia (AML) and carries a very poor prognosis. How EVI1 confers leukemic transformation and chemotherapy resistance in AML is subject to important ongoing clinical and experimental studies. Recent discoveries have revealed critical details on genetic mechanisms of the activation of EVI1 overexpression and downstream events of aberrantly high EVI1 expression. Here we review and discuss aspects concerning the protein interactions of EVI1 and the related proteins MDS-EVI1 and ΔEVI1 from the perspective of their potential for therapeutic intervention.

Identifiants

DOI: 10.1016/j.exphem.2021.12.398 PMID: 34958895
pubmed: 34958895
pii: S0301-472X(21)00857-2
doi: 10.1016/j.exphem.2021.12.398
pii:
doi:

Substances chimiques

DNA-Binding Proteins 0
MDS1 and EVI1 Complex Locus Protein 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Subventions

Organisme : Cancer Research UK
Pays : United Kingdom

Informations de copyright

Copyright © 2021 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors do not have any conflicts of interest to declare in relation to this work.

Auteurs

Roberto Paredes (R)

Stem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, National Institute for Health Research Biomedical Research Centre, Manchester, UK.

Nora Doleschall (N)

Stem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, National Institute for Health Research Biomedical Research Centre, Manchester, UK.

Kathleen Connors (K)

Stem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, National Institute for Health Research Biomedical Research Centre, Manchester, UK.

Bethany Geary (B)

Stem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, National Institute for Health Research Biomedical Research Centre, Manchester, UK.

Stefan Meyer (S)

Stem Cell and Leukaemia Proteomics Laboratory, Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Manchester Academic Health Science Centre, National Institute for Health Research Biomedical Research Centre, Manchester, UK; Department of Paediatric Haematology and Oncology, Royal Manchester Children's Hospital, Manchester, UK; Young Oncology Unit, The Christie NHS Foundation Trust, Manchester, UK. Electronic address: stefan.meyer@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de liaison à l'ADN › EVI1 protein interaction dynamics: Targetable...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › EVI1 protein interaction dynamics: Targetable...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › EVI1 protein interaction dynamics: Targetable...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéine du locus du complexe MDS1 et EVI1 › EVI1 protein interaction dynamics: Targetable...
questionsmedicales.fr › Diagnostic › Pronostic › EVI1 protein interaction dynamics: Targetable...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › EVI1 protein interaction dynamics: Targetable...